NEW YORK (GenomeWeb News) – Ligon Discovery today said that it will use its Small Molecule Microarray (SMM) screening platform to discover candidates for Bayer Schering Pharma's drug development programs.
The Cambridge, Mass.-based firm said that its technology works by affixing drug candidates to a slide, enabling it to use cell lysates, instead of "developing a complex assay based on a full understanding of a protein target's functions."